JP5744976B2 - にきびの治療方法発明の分野 - Google Patents
にきびの治療方法発明の分野 Download PDFInfo
- Publication number
- JP5744976B2 JP5744976B2 JP2013146709A JP2013146709A JP5744976B2 JP 5744976 B2 JP5744976 B2 JP 5744976B2 JP 2013146709 A JP2013146709 A JP 2013146709A JP 2013146709 A JP2013146709 A JP 2013146709A JP 5744976 B2 JP5744976 B2 JP 5744976B2
- Authority
- JP
- Japan
- Prior art keywords
- oral
- oral administration
- nosaikurin
- acne
- preparation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010000496 acne Diseases 0.000 title claims description 36
- 208000002874 Acne Vulgaris Diseases 0.000 title claims description 34
- 238000011282 treatment Methods 0.000 title description 17
- 238000009472 formulation Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 6
- 229960001021 lactose monohydrate Drugs 0.000 claims 6
- 238000002360 preparation method Methods 0.000 claims 6
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 claims 1
- 229960002421 minocycline hydrochloride Drugs 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 description 14
- 229940072172 tetracycline antibiotic Drugs 0.000 description 11
- 239000004098 Tetracycline Substances 0.000 description 10
- 235000019364 tetracycline Nutrition 0.000 description 10
- 150000003522 tetracyclines Chemical class 0.000 description 9
- 229960002180 tetracycline Drugs 0.000 description 8
- 229930101283 tetracycline Natural products 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 6
- 229960004023 minocycline Drugs 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000003325 follicular Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229960005280 isotretinoin Drugs 0.000 description 2
- 239000003410 keratolytic agent Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940127249 oral antibiotic Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- -1 tetracycline compounds Chemical class 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 206010063655 Erosive oesophagitis Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 206010049040 Weight fluctuation Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Description
Claims (9)
- 患者のためのにきび治療用経口投与剤であって、
前記経口投与剤が、
一日一回負荷量なしで投与されることで0.7〜1.3mg/kg/日のミノサイクリンが前記患者に与えられる量の前記ミノサイクリン、並びに、第1の乳糖一水和物、第2の乳糖一水和物、及びヒドロキシプロピルメチルセルロースを含む送達ビヒクルを含み、
前記第1の乳糖一水和物が、前記ヒドロキシプロピルメチルセルロースによって完全に又は部分的に被包又は被覆され、
前記第2の乳糖一水和物が、前記ヒドロキシプロピルメチルセルロースによって被包又は被覆されず、
前記第2の乳糖一水和物が前記ヒドロキシプロピルメチルセルロースに対して0.3〜0.5の質量比で存在する、
経口投与製剤。 - 前記0.7〜1.3mg/kg/日が、1.0mg/kg/日である請求項1記載の経口投与製剤。
- 前記ミノサイクリンは、ミノサイクリン塩酸塩である請求項1又は2に記載の経口投与製剤。
- 前記ヒドロキシプロピルメチルセルロースに対する前記第2の乳糖一水和物の前記質量比が、0.35〜0.45である請求項1から3のいずれかに記載の経口投与製剤。
- 前記質量比が、0.36〜0.40である請求項4記載の経口投与製剤。
- 前記ヒドロキシプロピルメチルセルロースが、
前記経口投与製剤が135mgの前記ミノサイクリンを含む場合には前記経口投与製剤中に23.5重量%存在し、又は、
前記経口投与製剤が45mgの前記ミノサイクリンを含む場合には前記経口投与製剤中に27.0重量%存在する請求項1から5のいずれかに記載の経口投与製剤。 - 前記経口投与製剤は、患者において投与後3.0〜3.75時間でCmaxに達する速度でミノサイクリンを放出する請求項1から6のいずれかに記載の経口投与製剤。
- 投与後3.5時間で前記Cmaxに達する請求項7記載の経口投与製剤。
- さらに、被覆体を含む請求項1から8のいずれかに記載の経口投与製剤。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/166,817 US7919483B2 (en) | 2005-06-24 | 2005-06-24 | Method for the treatment of acne |
US11/166,817 | 2005-06-24 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008518272A Division JP2008543936A (ja) | 2005-06-24 | 2006-06-19 | にきびの治療方法発明の分野 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013213047A JP2013213047A (ja) | 2013-10-17 |
JP5744976B2 true JP5744976B2 (ja) | 2015-07-08 |
Family
ID=37568356
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008518272A Pending JP2008543936A (ja) | 2005-06-24 | 2006-06-19 | にきびの治療方法発明の分野 |
JP2013146709A Active JP5744976B2 (ja) | 2005-06-24 | 2013-07-12 | にきびの治療方法発明の分野 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008518272A Pending JP2008543936A (ja) | 2005-06-24 | 2006-06-19 | にきびの治療方法発明の分野 |
Country Status (11)
Country | Link |
---|---|
US (6) | US7919483B2 (ja) |
EP (1) | EP1898925A4 (ja) |
JP (2) | JP2008543936A (ja) |
CN (1) | CN101208097A (ja) |
AU (1) | AU2006262428B2 (ja) |
CA (1) | CA2613273C (ja) |
IL (1) | IL188331A0 (ja) |
NO (1) | NO20080444L (ja) |
NZ (1) | NZ564093A (ja) |
WO (1) | WO2007001961A2 (ja) |
ZA (1) | ZA200802064B (ja) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110092677A1 (en) * | 2001-08-30 | 2011-04-21 | Biorexis Technology, Inc. | Modified transferin-antibody fusion proteins |
WO2005011707A1 (en) | 2003-07-25 | 2005-02-10 | Warner Chilcott Company, Inc. | A doxycycline metal complex in a solid dosage form |
CA2595481C (en) * | 2005-01-21 | 2014-05-13 | Warner Chilcott Company, Inc. | A tetracycline metal complex in a solid dosage form |
US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
US20080242642A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US9192615B2 (en) | 2008-08-06 | 2015-11-24 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
US8252776B2 (en) * | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US7541347B2 (en) * | 2007-04-02 | 2009-06-02 | Medicis Pharmaceutical Coropration | Minocycline oral dosage forms for the treatment of acne |
US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US7544373B2 (en) * | 2007-04-02 | 2009-06-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US20100215744A1 (en) * | 2008-08-06 | 2010-08-26 | Medicis Pharmaceutical Corporation | Hydroxypropyl Substitution Used to Regulate Dissolution of a Chemical |
KR20130137696A (ko) * | 2007-03-23 | 2013-12-17 | 몰레큘러 리서치 센터, 인크. | 테트라사이클린류를 함유하는 항염증성 조성물 및 이의 치료 용도 |
US20080241197A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline dosage forms for the treatment of acne |
WO2008121107A1 (en) * | 2007-04-02 | 2008-10-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US20120027855A1 (en) * | 2007-07-06 | 2012-02-02 | Lupin Limited | Pharmaceutical compositions for gastrointestinal drug delivery |
WO2012153884A1 (ko) * | 2011-05-12 | 2012-11-15 | (주)아모레퍼시픽 | 안정성이 향상된 여드름 개선용 조성물 |
US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
ES2704125T3 (es) | 2015-01-26 | 2019-03-14 | Bausch & Lomb | Composición de suspensión oftálmica |
BR112017020358A2 (pt) | 2015-03-23 | 2018-07-17 | Biopharmx Inc | composição farmacêutica de tetraciclina para uso dermatológico |
WO2016162754A1 (en) | 2015-04-07 | 2016-10-13 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions for minocycline |
CA3087838A1 (en) * | 2018-01-07 | 2019-07-11 | Dr. Reddy's Laboratories Ltd. | Minocycline for treating inflammatory skin conditions |
CN111210890B (zh) * | 2020-02-14 | 2023-06-16 | 成都木老仁康软件信息有限公司 | 一种基于临床数据的抗凝药学监护管理方法 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3966922A (en) | 1971-07-23 | 1976-06-29 | Takeda Chemical Industries, Ltd. | Composition for poultry and livestock |
US3957980A (en) * | 1972-10-26 | 1976-05-18 | Pfizer Inc. | Doxycycline parenteral compositions |
JPS5418330B2 (ja) | 1973-03-16 | 1979-07-06 | ||
US4018889A (en) * | 1976-01-02 | 1977-04-19 | Pfizer Inc. | Oxytetracycline compositions |
US4126680A (en) * | 1977-04-27 | 1978-11-21 | Pfizer Inc. | Tetracycline antibiotic compositions |
US4443442A (en) * | 1979-12-21 | 1984-04-17 | Skillern Scott D | Method and composition for treatment of acne vulgaris |
US4376118A (en) * | 1980-10-06 | 1983-03-08 | Miles Laboratories, Inc. | Stable nonaqueous solution of tetracycline salt |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4376172A (en) * | 1982-02-01 | 1983-03-08 | Cincinnati Milacron Inc. | Closed loop control of compressible fluid addition to a mixture of such fluid and a liquid |
US4806529A (en) | 1982-11-18 | 1989-02-21 | Trustees Of Tufts College, Tufts University | Tetracycline activity enhancement |
US4764377A (en) | 1983-10-07 | 1988-08-16 | The Forsyth Dental Infirmary For Children | Intra-pocket drug delivery devices for treatment of periodontal diseases |
US4935412A (en) * | 1983-12-29 | 1990-06-19 | The Research Foundation Of State University Of New York | Non-antibacterial tetracycline compositions possessing anti-collagenolytic properties and methods of preparing and using same |
US4925833A (en) * | 1983-12-29 | 1990-05-15 | The Research Foundation Of State University Of New York | Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis |
US4701320A (en) | 1984-11-29 | 1987-10-20 | Lederle (Japan), Ltd. | Composition stably containing minocycline for treating periodontal diseases |
US5209978A (en) * | 1985-12-26 | 1993-05-11 | Taisho Pharmaceutical Co., Ltd. | Seamless soft capsule and production thereof |
AU618517B2 (en) | 1986-12-23 | 1992-01-02 | Eugene J. Van Scott | Additives enhancing topical actions of therapeutic agents |
US5389677B1 (en) | 1986-12-23 | 1997-07-15 | Tristrata Inc | Method of treating wrinkles using glycalic acid |
US4792448A (en) * | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
HU198173B (en) | 1987-09-18 | 1989-08-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing doxycycline |
US4837030A (en) * | 1987-10-06 | 1989-06-06 | American Cyanamid Company | Novel controlled release formulations of tetracycline compounds |
US5211958A (en) | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
US5277916A (en) * | 1988-02-01 | 1994-01-11 | F. H. Faulding & Co., Ltd. | Tetracycline dosage form |
US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
ATE128959T1 (de) * | 1989-01-24 | 1995-10-15 | Spi Polyols Inc | Kryoschützende kristalline sorbitolkügelchen. |
US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
US5122519A (en) | 1989-06-27 | 1992-06-16 | American Cyanamid Company | Stable, cosmetically acceptable topical gel formulation and method of treatment for acne |
KR920702383A (ko) * | 1989-08-28 | 1992-09-03 | 원본미기재 | 치료제의 방출을 조절하는데 유용한 생부식성 중합체 |
IL95423A (en) | 1989-09-21 | 1994-11-11 | American Cyanamid Co | Pulse system for delivery of minocycline once daily |
EP0418596A3 (en) | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
EP0418597A3 (en) | 1989-09-21 | 1991-11-27 | American Cyanamid Company | Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form |
JP3016587B2 (ja) * | 1989-12-04 | 2000-03-06 | ザ・リサーチ・ファンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク | 非ステロイド抗炎症剤及びテトラサイクリンの配合 |
US5230895A (en) | 1990-05-01 | 1993-07-27 | Copley Pharmaceutical Inc. | Sustained released delivery system for use in the periodontal pocket |
US5188836A (en) | 1990-07-27 | 1993-02-23 | Warner-Lambert Company | Sustained release formulations |
FI922107A0 (fi) | 1991-05-10 | 1992-05-08 | Faulding F H & Co Ltd | Mikrokapselkomposition och foerfarande. |
WO1993007902A1 (en) | 1991-10-16 | 1993-04-29 | Richardson-Vicks, Inc. | Enhanced skin penetration system for improved topical delivery of drugs |
US5167964A (en) | 1992-02-14 | 1992-12-01 | Warner-Lambert Company | Semi-enteric drug delivery systems and methods for preparing same |
US5262173A (en) * | 1992-03-02 | 1993-11-16 | American Cyanamid Company | Pulsatile once-a-day delivery systems for minocycline |
US5217493A (en) | 1992-03-11 | 1993-06-08 | Board Of Regents, The University Of Texas System | Antibacterial coated medical implants |
US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
JPH07507059A (ja) | 1992-03-25 | 1995-08-03 | デポムド システムズ,インコーポレイテッド | アルキル置換セルロースをベースとする持続放出性経口薬剤投与剤形 |
US5518730A (en) | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
WO1994003160A1 (en) * | 1992-08-05 | 1994-02-17 | F.H. Faulding & Co. Limited | Pelletised pharmaceutical composition |
AU1279095A (en) * | 1994-02-17 | 1995-09-04 | Pfizer Inc. | 9-(substituted amino)-alpha-6-deoxy-5-oxy tetracycline derivatives, their preparation and their use as antibiotics |
KR960016882A (ko) | 1994-11-01 | 1996-06-17 | 강재헌 | 치주염치료를 위한 서방출형 생분해성 제제 |
US5674539A (en) | 1994-12-09 | 1997-10-07 | Tomas; Robert E. | Method of treating skin and composition |
EP0823893A1 (en) * | 1995-05-03 | 1998-02-18 | Pfizer Inc. | Novel tetracycline derivatives |
AUPN605795A0 (en) * | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
US5814331A (en) * | 1995-11-13 | 1998-09-29 | Holen; Sheldon | Process for inhibiting pathogenic bacteria in the oral cavity and for binding peptide growth factors on surfaces |
US5783212A (en) * | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
US5789395A (en) * | 1996-08-30 | 1998-08-04 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds for inhibition of endogenous nitric oxide production |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US8828432B2 (en) * | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
US6429204B1 (en) | 1997-01-15 | 2002-08-06 | University Of Miami | Method of inhibiting cancer growth |
EP0998271B3 (en) | 1997-06-06 | 2014-10-29 | Depomed, Inc. | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
CA2293815C (en) | 1997-06-11 | 2004-06-29 | The Procter & Gamble Company | Film-coated tablet for improved upper gastrointestinal tract safety |
PT1003476E (pt) | 1997-08-11 | 2005-05-31 | Alza Corp | Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica |
US5908838A (en) * | 1998-02-19 | 1999-06-01 | Medics Pharmaceutical Corporation | Method for the treatment of acne |
KR100296413B1 (ko) * | 1998-04-01 | 2001-11-14 | 김선진 | 세파클러함유서방성정제 |
CA2331257C (en) * | 1998-05-08 | 2012-01-03 | University Of Miami | Use of tetracyclines for treating meibomian gland disease |
US6015804A (en) * | 1998-09-11 | 2000-01-18 | The Research Foundation Of State University Of New York | Method of using tetracycline compounds to enhance interleukin-10 production |
US6506740B1 (en) | 1998-11-18 | 2003-01-14 | Robert A. Ashley | 4-dedimethylaminotetracycline derivatives |
US6087382A (en) * | 1999-03-17 | 2000-07-11 | Bonner, Jr.; Ernest L. | Method for treatment of reactive arthritis or bursitis |
BR0009437A (pt) * | 1999-03-31 | 2002-01-15 | Janssen Pharmaceutica Nv | Amido pré-gelatinizado em uma formulação de liberação controlada |
JP2002541093A (ja) | 1999-04-06 | 2002-12-03 | ファーマクエスト・リミテッド | d−threo−メチルフェニデートおよび第2のCNS刺激薬のパルス性送達のための薬学的投薬形態 |
US6673843B2 (en) * | 1999-06-30 | 2004-01-06 | Emory University | Curcumin and curcuminoid inhibition of angiogenesis |
US6497902B1 (en) * | 1999-12-01 | 2002-12-24 | The Regents Of The University Of Michigan | Ionically crosslinked hydrogels with adjustable gelation time |
AP2002002553A0 (en) | 1999-12-23 | 2002-06-30 | Pfizer Prod Inc | Hydrogel-driven Drug Dosoge Form. |
JP3888064B2 (ja) * | 2000-01-27 | 2007-02-28 | 田辺製薬株式会社 | 徐放性製剤およびその製法 |
WO2001070288A2 (en) * | 2000-03-23 | 2001-09-27 | Genetics Institute, Inc. | Thermoreversible polymers for delivery and retention of osteoinductive proteins |
DE60212613T2 (de) * | 2001-04-05 | 2007-05-24 | Collagenex Pharmaceuticals, Inc. | Doxycyclin zur behandlung von akne |
US7211267B2 (en) | 2001-04-05 | 2007-05-01 | Collagenex Pharmaceuticals, Inc. | Methods of treating acne |
KR100982753B1 (ko) | 2001-04-05 | 2010-09-16 | 콜라제넥스 파마슈티칼스, 인크 | 테트라사이클린 화합물 및 테트라사이클린 유도체의 전달조절 |
US6585997B2 (en) * | 2001-08-16 | 2003-07-01 | Access Pharmaceuticals, Inc. | Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
CA2409552A1 (en) * | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
US20030082120A1 (en) * | 2001-10-26 | 2003-05-01 | Milstein Harold J. | Method for reducing systemic effects of aging, effects of aging on the skin, and incidence of skin damage from sun exposure using antibiotics of the tetracycline family |
US6958161B2 (en) | 2002-04-12 | 2005-10-25 | F H Faulding & Co Limited | Modified release coated drug preparation |
NZ534613A (en) | 2002-04-16 | 2007-07-27 | Collagenex Pharm Inc | Methods of simultaneously treating ocular rosacea and acne rosacea with a tetracycline compound |
US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
CA2499599A1 (en) | 2002-09-17 | 2004-04-01 | New York University | Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors |
JP4443834B2 (ja) * | 2003-01-24 | 2010-03-31 | 杏林製薬株式会社 | 徐放性錠剤およびその製造方法 |
WO2004078111A2 (en) | 2003-03-06 | 2004-09-16 | Ranbaxy Laboratories Limited | Extended release minocycline compositions and processes for their preparation |
ES2391385T3 (es) | 2003-04-07 | 2012-11-23 | Supernus Pharmaceuticals, Inc. | Formulaciones de doxiciclinas en dosis única diaria |
US6863830B1 (en) * | 2003-08-21 | 2005-03-08 | Biolab Services, Inc. | Dual layer tablet, method of making and use thereof |
EP1684768A4 (en) | 2003-11-06 | 2007-06-06 | Univ New York State Res Found | METHOD FOR TREATING ECCEM |
US7943585B2 (en) | 2003-12-22 | 2011-05-17 | Sandoz, Inc. | Extended release antibiotic composition |
GB2414668B (en) | 2004-06-03 | 2009-07-29 | Dexcel Ltd | Tetracycline modified release delivery system |
US20080242642A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US7541347B2 (en) * | 2007-04-02 | 2009-06-02 | Medicis Pharmaceutical Coropration | Minocycline oral dosage forms for the treatment of acne |
US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US8252776B2 (en) * | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US7544373B2 (en) * | 2007-04-02 | 2009-06-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
US20080241197A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline dosage forms for the treatment of acne |
-
2005
- 2005-06-24 US US11/166,817 patent/US7919483B2/en active Active
-
2006
- 2006-06-19 AU AU2006262428A patent/AU2006262428B2/en active Active
- 2006-06-19 CN CNA2006800224203A patent/CN101208097A/zh active Pending
- 2006-06-19 WO PCT/US2006/023761 patent/WO2007001961A2/en active Application Filing
- 2006-06-19 JP JP2008518272A patent/JP2008543936A/ja active Pending
- 2006-06-19 CA CA2613273A patent/CA2613273C/en active Active
- 2006-06-19 NZ NZ564093A patent/NZ564093A/en unknown
- 2006-06-19 EP EP06773507A patent/EP1898925A4/en not_active Withdrawn
-
2007
- 2007-07-12 US US11/776,711 patent/US20080181945A2/en not_active Abandoned
- 2007-07-12 US US11/776,669 patent/US20080182825A2/en not_active Abandoned
- 2007-07-12 US US11/776,691 patent/US20070275933A1/en not_active Abandoned
- 2007-07-12 US US11/776,676 patent/US20080182826A2/en not_active Abandoned
- 2007-11-21 US US11/944,186 patent/US20080182827A2/en not_active Abandoned
- 2007-12-23 IL IL188331A patent/IL188331A0/en active IP Right Grant
-
2008
- 2008-01-23 NO NO20080444A patent/NO20080444L/no not_active Application Discontinuation
- 2008-03-05 ZA ZA200802064A patent/ZA200802064B/xx unknown
-
2013
- 2013-07-12 JP JP2013146709A patent/JP5744976B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
AU2006262428A1 (en) | 2007-01-04 |
NO20080444L (no) | 2008-01-23 |
US20070259039A1 (en) | 2007-11-08 |
JP2013213047A (ja) | 2013-10-17 |
AU2006262428B2 (en) | 2012-02-23 |
EP1898925A2 (en) | 2008-03-19 |
US20070254855A1 (en) | 2007-11-01 |
US20070275933A1 (en) | 2007-11-29 |
ZA200802064B (en) | 2009-09-30 |
US20080070872A1 (en) | 2008-03-20 |
WO2007001961A3 (en) | 2007-05-18 |
CA2613273C (en) | 2015-12-08 |
US20080182825A2 (en) | 2008-07-31 |
US20080182827A2 (en) | 2008-07-31 |
US20080181945A2 (en) | 2008-07-31 |
US20070270390A1 (en) | 2007-11-22 |
EP1898925A4 (en) | 2009-07-29 |
US20070225262A2 (en) | 2007-09-27 |
NZ564093A (en) | 2011-06-30 |
CA2613273A1 (en) | 2007-01-04 |
IL188331A0 (en) | 2008-08-07 |
US7919483B2 (en) | 2011-04-05 |
JP2008543936A (ja) | 2008-12-04 |
WO2007001961A2 (en) | 2007-01-04 |
CN101208097A (zh) | 2008-06-25 |
US20080182826A2 (en) | 2008-07-31 |
US20060293290A1 (en) | 2006-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5744976B2 (ja) | にきびの治療方法発明の分野 | |
KR102049253B1 (ko) | 리팍시민을 함유하는 약학적 제형, 그의 수득 방법 및 장 질환을 치료하는 방법 | |
MXPA05001538A (es) | Distribuidor de tipo manguito de endoscopio. | |
CA2601289A1 (en) | Once-a-day oxycodone formulations | |
Alikhan et al. | The role of tetracyclines in rosacea | |
US20070298098A1 (en) | Controlled Release Compositions Comprising Levetiracetam | |
KR102479497B1 (ko) | 바레니클린 서방성 제제 및 이의 제조 방법 | |
JP2020535227A5 (ja) | ||
JP2021520400A (ja) | エダラボン医薬組成物 | |
JP2009514963A (ja) | 肉芽腫性酒さの治療ためのアジスロマイシン | |
WO2006088864A1 (en) | Controlled release compositions comprising levetiracetam | |
JP2010538066A (ja) | 皮膚疾患治療用アジスロマイシン | |
US20060198886A1 (en) | Medicament having coated methenamine combined with acidifier | |
EP1880722B1 (en) | Pharmaceutical compositions of ciprofloxacin | |
KR20120089623A (ko) | 정맥내 투여용 이부프로펜을 이용한 환자의 치료 | |
JP2004091473A (ja) | 色素沈着改善治療薬 | |
JP2021509409A (ja) | 炎症性皮膚状態を処置するためのミノサイクリン | |
AU2022351983A1 (en) | Composition and method for prevention and treatment of cutaneous radiation injury | |
TW200812645A (en) | Tetracycline package formulations | |
MXPA05001559A (es) | Composiciones de mononitrato de isosorbide y metodos de uso de las mismas. | |
CN114401724B (zh) | 一种降糖药物组合物 | |
JP2018536690A (ja) | 皮膚障害の治療用医薬製剤、ならびにその製造方法および用法 | |
KR20200031126A (ko) | 비염증성 병변의 치료 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130712 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141029 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150414 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150430 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5744976 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |